Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 3 pseudogene 30 (HMGB3P30) is a processed pseudogene related to the high mobility group box 3 (HMGB3) gene family. **Pseudogenes** are genomic DNA sequences similar to normal genes but are non-functional; they arise from gene duplication or retrotransposition followed by disabling mutations[4]. Pseudogenes such as HMGB3P30 generally do not encode proteins and are not classified as enzymes, receptors, transporters, or other conventional therapeutic targets[4]. While some pseudogenes have gained novel regulatory functions (e.g., acting as competitive endogenous RNAs or decoys for microRNAs), there is currently no documented evidence that HMGB3P30 has any such function[3]. Most pseudogenes are considered "genomic fossils" or "junk DNA," though research continues into possible regulatory activities for select pseudogenes. HMGB3P30 is a non-coding, non-functional processed pseudogene; it is not a therapeutic target, not a protein, not implicated in disease or drug interactions, and does not encode a receptor or enzyme. The main concern is confusion due to its similarity in name to functional HMGB gene family members[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 3 pseudogene 30 (HMGB3P30).